Gasparian M G, Dzhagatspanian N G, Gevorkian R A, Kamalian L A
Vopr Virusol. 1991 Mar-Apr;36(2):127-30.
The paper presents the results of experimental and clinical studies on the antitumor effect of larifan. A statistically significant inhibition of growth of some continuous mouse tumors by larifan in a dose of 2.5 mg/kg given for 5-6 days and by a combination of larifan with an immunomodulator, inosiplex, tested on hepatoma XXIIa which has a rather low sensitivity to larifan. The antitumor effect of larifan may be due to interferon production and immunomodulating effect. Treatment with 0.05% larifan ointment of patients with cervical dysplasia of moderate degree resulted in a significant increase of previously diminished production of alpha-interferon after 10-14 vaginal tampons and clinical cure in 88% of cases. A course of 8-10-day larifan monotherapy given before radial therapy resulted in a considerable improvement in patients with cervical cancer of II-III stages, and subsequently, for 1 1/2-month combined radial therapy, no significant changes in production of alpha-IF were observed. At the same time, in patients with cervical cancer treated by radial therapy alone a significant decrease of alpha-IF production by blood mononuclears was observed by the end of therapy.
本文介绍了关于拉立泛抗肿瘤作用的实验和临床研究结果。拉立泛以2.5毫克/千克的剂量给药5 - 6天，对一些连续性小鼠肿瘤的生长有统计学显著抑制作用；在对拉立泛敏感性较低的XXIIa型肝癌上进行试验时，拉立泛与免疫调节剂肌苷肽联合使用也有此效果。拉立泛的抗肿瘤作用可能归因于干扰素的产生和免疫调节作用。用0.05%拉立泛软膏治疗中度宫颈发育异常患者，在使用10 - 14个阴道棉塞后，先前减少的α - 干扰素产生量显著增加，88%的病例实现临床治愈。在放射治疗前进行8 - 10天的拉立泛单一疗法疗程，使II - III期宫颈癌患者有相当大的改善，随后在为期1个半月的联合放射治疗期间，未观察到α - 干扰素产生量有显著变化。与此同时，在仅接受放射治疗的宫颈癌患者中，治疗结束时观察到血液单核细胞产生的α - 干扰素显著减少。
